BIOFORCE NANOSCIENCES HOLDINGS, INC. — Key Metrics
2 years of history · ending 2019-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Turnover & Efficiency Analysis (days)
Working Capital Analysis
52-Week Range
Trailing Returns
ROIC vs WACC
EPS (Diluted)
—
Book Value Per Share
—
Free Cash Flow Per Share
—
Cash Per Share
—
OCF Per Share
—
Return on Equity
-120.7%
Return on Assets
-99.0%
Return on Invested Capital
-95.4%
Current Ratio
5.08
Quick Ratio
5.08
Asset Turnover
0.38
Days Sales Outstanding
128.34
Working Capital
$47K
Net Current Asset Value
$47K
Invested Capital
$47K
OCF / Net Income
0.52
FCF / Net Income
0.52
Accruals Ratio (Sloan)
-37.6%
Net Debt
$-53K
Net Debt / EBITDA
1.14
Tangible Common Equity
$47K
TCE / Total Assets
80.3%
NOPAT
$-37K
Cash ROIC
-63.2%
WC / Revenue
266.1%
Asset Growth vs Revenue Growth
58.7%
Stock Price (FY-end)
$1
Market Cap
—
Enterprise Value
—
FCF Yield
—
Shares Variation (YoY)
—
Beta (5Y)
0.76
Cost of Equity
8.3%
52W High
$10
52W Low
$1
Trailing Return 1Y
-85.3%
Trailing Return 5Y
433.3%
F-Score (Piotroski)
2.00
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.